Covid 19 Research using Clinical Trials (Home Page)
HP:0001287: MeningitisHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1464 | Venepuncture Wiki | 1.00 |
| drug947 | Oral fluid swab Wiki | 1.00 |
Correlated MeSH Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008585 | Meningitis, Meningococcal NIH | 1.00 |
| D008581 | Meningitis, Mening NIH | 1.00 |
| D004165 | Diphtheria NIH | 1.00 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Serum Testing of Representative Youngsters: Sero- Epidemiological Survey of England in 2019/2020
This is a pilot study to assess the feasibility of establishing a national sero-epidemiological survey in England in individuals aged 0-24 years, focusing on assessing humoral immunity against diphtheria, Group C invasive meningococcus and SARS-CoV-2. The investigators will recruit 2800 to 3500 individuals, divided into two groups: Group one (N= 2300): This will include all age groups (0-24years), with recruitment restricted by postcodes provided by Public Health England (PHE) to recruit a representative population for the region as assessed by the IMD (Index of Multiple Deprivation scores). Group two (N= up to 1200): This group has been added following additional funding to enhance the sample size in response to the COVID-19 pandemic. This will recruit 0-19 year olds and will not be restricted by post code sampling. Instead recruitment will be by public promotion within the normal recruiting regions for each site.
NCT04061382 Serogroup C Meningococcal Meningitis Diphtheria COVID-19 Procedure: Venepuncture Procedure: Oral fluid swab MeSH:Diphtheria Meningitis, Meningococcal Meningitis
HPO:Meningitis
Primary Outcomes
Description: Measure the representativeness of participants as compared to the census data for the study region.
Measure: Feasibility of developing an England based sero-epidemiological programme in 0-24 year olds Time: 11months
Description: Test serological markers of immunity for vaccine preventable diseases starting with diphtheria.
Measure: Feasibility of developing an England based sero epidemiological survey in 0-24 year olds Time: 11 months
Description: Test serological markers of immunity for vaccine preventable diseases including Invasive Meningococcal type C.
Measure: Feasibility of developing an England based sero epidemiological survey in 0-24 year olds Time: 11 months
Description: Test serological markers to determine the true number of infections with SARS-CoV-2 in the population.
Measure: Feasibility of developing an England based sero epidemiological survey in 0-24 year olds Time: 11 months
Secondary Outcomes
Description: Recruitment rate per month, recruitment rates as percentage of potential participants contacted
Measure: Recruitment rate Time: 11 Months
Description: Cost per sample obtained of 'disease specific correlates of protection/markers of immunity, e.g. Anti-Diphtheria Toxoid IgG concentrations and Capsular Group C meningococcal Serum bactericidal activity (SBA) titres and Serum IgG to SARS-CoV-2 antigens, including spike protein (as measured by ELISA and/or neutralising assay)
Measure: Cost Time: 12 months
Description: IgG to COVID-19 spike protein
Measure: To assess, in relevant age groups, antibody concentrations against infections and vaccine preventable diseases Time: 11 months
Description: A collection of anonymised sera from participants with appropriate consent and known demographic details and immunisation history.
Serum IgG to SARS-CoV-2 antigens, including spike protein (as measured by ELISA and/or neutralising assay)
Measure: Sera collection Time: 11 months
Description: • Representativeness of participants sampled, in terms of the local population's ethnicity, community identity, migrant population and socioeconomic background in group 1 and group 2.
Differences in immunological read outs
PCR for SARS-CoV-2 on saliva samples this will be stored and processed at the end of the study.
IgA to SARS-CoV-2 in saliva paired with serum samples.
Measure: Exploratory Time: 11 months
HPO Nodes
HP:0001287: Meningitis
Genes 77
TNFRSF13C MEFV BCL2 CARD9 CXCR4 PTPN22 PIK3R1 PRF1 C4B JAK3 CD79A TLR4 CYBB HLA-DPA1 RAG2 STAT4 KLRC4 BLNK RFXAP TCF3 IL10 FAS TLR3 CCR1 IGH HLA-B IL12A CIITA BTK TFRC LRRC8A HLA-DPB1 XIAP NLRP3 FOXP3 CD19 HLA-DRB1 NCF4 WAS SH2D1A WAS MEFV C4A RFXANK WIPF1 UBAC2 NLRP3 PTPN22 IL12A-AS1 ERAP1 CD79B IGHM RAG1 NCF1 CYBC1 IL23R IGLL1 DNASE1L3 TBK1 TNFRSF13B CTLA4 PRTN3 CYBA C8B IGLL1 MEFV VANGL1 BTK C8A RFX5 ICOS BTK NLRC4 CR2 BCL6 NDE1 NCF2 Protein Mutations 0
SNP 0
Primary Outcomes
Description: Measure the representativeness of participants as compared to the census data for the study region.
Measure: Feasibility of developing an England based sero-epidemiological programme in 0-24 year olds Time: 11monthsDescription: Test serological markers of immunity for vaccine preventable diseases starting with diphtheria.
Measure: Feasibility of developing an England based sero epidemiological survey in 0-24 year olds Time: 11 monthsDescription: Test serological markers of immunity for vaccine preventable diseases including Invasive Meningococcal type C.
Measure: Feasibility of developing an England based sero epidemiological survey in 0-24 year olds Time: 11 monthsDescription: Test serological markers to determine the true number of infections with SARS-CoV-2 in the population.
Measure: Feasibility of developing an England based sero epidemiological survey in 0-24 year olds Time: 11 monthsSecondary Outcomes
Description: Recruitment rate per month, recruitment rates as percentage of potential participants contacted
Measure: Recruitment rate Time: 11 MonthsDescription: Cost per sample obtained of 'disease specific correlates of protection/markers of immunity, e.g. Anti-Diphtheria Toxoid IgG concentrations and Capsular Group C meningococcal Serum bactericidal activity (SBA) titres and Serum IgG to SARS-CoV-2 antigens, including spike protein (as measured by ELISA and/or neutralising assay)
Measure: Cost Time: 12 monthsDescription: IgG to COVID-19 spike protein
Measure: To assess, in relevant age groups, antibody concentrations against infections and vaccine preventable diseases Time: 11 monthsDescription: A collection of anonymised sera from participants with appropriate consent and known demographic details and immunisation history. Serum IgG to SARS-CoV-2 antigens, including spike protein (as measured by ELISA and/or neutralising assay)
Measure: Sera collection Time: 11 monthsDescription: • Representativeness of participants sampled, in terms of the local population's ethnicity, community identity, migrant population and socioeconomic background in group 1 and group 2. Differences in immunological read outs PCR for SARS-CoV-2 on saliva samples this will be stored and processed at the end of the study. IgA to SARS-CoV-2 in saliva paired with serum samples.
Measure: Exploratory Time: 11 months